Antiphospholipid syndrome (APS), also known as Hughes syndrome or sticky blood syndrome, is an autoimmune disorder in which the immune system makes antibodies against fat-protein components on the surface of cells and platelets. These antibodies make the blood more likely to clot, so APS is classed as a thrombophilia.
The main antibodies are lupus anticoagulant, anticardiolipin antibodies and anti-beta-2 glycoprotein I antibodies. They raise the risk of repeated clots in veins and arteries, which can lead to pulmonary embolism, heart attack, stroke or kidney damage. APS is also linked with a low platelet count and with pregnancy problems such as pre-eclampsia and recurrent miscarriage. Rarely, widespread clotting damages many organs at once, known as catastrophic APS.
Anyone can be affected, but it is more common in women of childbearing age and in people with another autoimmune disease such as lupus. The antibodies can also appear for a while with infections or certain medicines, or in healthy people without symptoms.
Symptoms differ from person to person and depend on where a clot forms. Clots often develop in the deep veins of the legs and can travel to the lungs; they may also block arteries in the arms or legs. Pregnancy, immobility, surgery, smoking, oral contraceptives and high cholesterol all raise the risk.
Possible signs include a painful, red, swollen arm or leg, chest pain, breathlessness, persistent headaches, stroke, seizures, memory loss or changes in speech and thinking, nausea, a lacy red rash on the limbs (livedo reticularis) and skin ulcers. Some women have repeated miscarriages, pre-eclampsia or premature birth without any other symptoms. Bleeding can occur when the platelet count is very low.
Not everyone with antiphospholipid antibodies has symptoms, so diagnosis needs both a clinical event and a positive antibody test. Clinical events are a confirmed clot in an artery, vein or small vessel, or pregnancy problems: an unexplained loss of a normal foetus from the 10th week, premature birth by the 34th week because of pre-eclampsia or a poorly working placenta, or three or more unexplained early miscarriages in a row. The antibody test must be positive at least twice, 12 or more weeks apart.
Blood tests for the antibodies are lupus anticoagulant testing (such as the dilute Russell viper venom test, DRVVT), anticardiolipin antibodies and beta-2 glycoprotein I antibodies. PTT, PT, a mixing study and a full blood count (FBC) help assess clotting and platelets.
CT, MRI, ultrasound and echocardiography can locate clots, check for organ and heart valve damage, and monitor the baby during pregnancy.
APS cannot be cured, so treatment aims to prevent new clots, treat existing ones and limit organ damage. People with the antibodies who have never had a clot or miscarriage are not usually treated.
Avoiding other clotting risks such as smoking and oral contraceptives helps, as does managing any linked autoimmune disease. Clots are treated with anticoagulants such as heparin and warfarin, and long-term anticoagulation is often needed to stop them returning; aspirin may be used for people at risk of heart attack.
Women with APS can have successful pregnancies with close monitoring, often using heparin injections and/or low-dose aspirin, since warfarin cannot be used in pregnancy. Catastrophic APS needs combined treatment with anticoagulants, steroids and plasma exchange, sometimes with intravenous immunoglobulin.